Targeting Vector Interactome to Enhance CFTR Delivery
靶向载体相互作用组以增强 CFTR 传递
基本信息
- 批准号:9404181
- 负责人:
- 金额:$ 23.85万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-30 至 2019-07-31
- 项目状态:已结题
- 来源:
- 关键词:Adenomatous Polyposis ColiAgonistAirAlpha CellAnimalsBindingBiologyBloodCell membraneCellsClinicalClinical TrialsCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorDNADNA receptorDevelopmentEpithelial CellsFDA approvedGene DeliveryGene ExpressionGene ProteinsGene TransferGenesGlucocorticoid ReceptorGoalsHeat-Shock Proteins 90HumanImmune responseIn VitroLiquid substanceLogicMeasurementMediatingMicroscopyMucous body substanceNuclearNucleic AcidsPharmacologyPhysiologicalPolyethylene GlycolsProteinsRNAReporterReporter GenesReportingResearch PersonnelReverse Transcriptase Polymerase Chain ReactionRoleSiteTechniquesTestingTherapeuticTherapeutic EffectToxic effectTransfectionTranslatingVirusWestern Blottingairway surface liquidalpha Spectrinbaseclinical efficacyclinically relevantcystic fibrosis airwaycystic fibrosis mousecystic fibrosis patientsextracellulargene therapyimprovedin vivointravenous administrationinventionnanoparticlenovel strategiesnucleolinparticleprotein functionsmall hairpin RNAsmall moleculesuccesstherapeutic geneuptakevector
项目摘要
Abstract
DNA nanoparticles have been tested in CF patients and shown to be safe and able to deliver nucleic acids to
the airway. We have reported that nucleolin interaction with glucocorticoid receptor (GR) is essential for
cellular binding and transfection of DNPs and discovered that DNPs interact with other proteins in human
primary airway epithelial cells, including adenomatous polyposis coli (APC), and non-erythrocytic spectrin
alpha 1 (SPTAN1). These interactions can significantly modulate DNPs-mediated gene transfer, which prompts
our hypothesis that DNP interaction with GR, HSP90, APC, and SPTAN1 modulate nucleolin-mediated
transport of the particles and that the interactions can be manipulated with agents approved in humans to
enhance gene delivery in vivo. To investigate the hypothesis, our specific aims are: 1) To evaluate the impact
of manipulating the DNP interactome on gene delivery and toxicity in vivo; and 2) To examine the mechanisms
that enhance gene transfer in well differentiated airway epithelial cells from CF patients. The proposed studies
will be the first to explore the biology of DNPs and improve our understanding of important steps in delivery.
Furthermore, the studies have the potential of defining small molecules already approved for use in humans as
agents that can be administered before or during nanoparticle administration to significantly enhance gene
transfer of CFTR into the therapeutic range.
摘要
DNA纳米颗粒已经在CF患者中进行了测试,并且显示出是安全的,并且能够将核酸递送到CF患者。
气道。我们已经报道了核仁素与糖皮质激素受体(GR)的相互作用是必不可少的,
细胞结合和转染,并发现DNPs与人类中的其他蛋白质相互作用,
原代气道上皮细胞,包括腺瘤性结肠息肉病(APC)和非红细胞血影蛋白
α 1(SPTAN1)。这些相互作用可以显著调节DNP介导的基因转移,这促使
我们假设DNP与GR、HSP 90、APC和SPTAN 1的相互作用调节核仁素介导的
颗粒的运输,并且可以用在人体中批准的试剂操纵相互作用,
增强体内基因递送。为了研究这一假设,我们的具体目标是:1)评估影响
操纵DNP相互作用组对体内基因递送和毒性的影响;和2)研究DNP相互作用组对体内基因递送和毒性的作用机制。
其增强来自CF患者的分化良好的气道上皮细胞中的基因转移。拟议的研究
将是第一个探索DNP生物学并提高我们对交付重要步骤的理解。
此外,这些研究有可能将已经批准用于人类的小分子定义为
可以在纳米颗粒给药之前或期间给药以显著增强基因表达的试剂
将CFTR转移到治疗范围内。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
John Paul Clancy其他文献
John Paul Clancy的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('John Paul Clancy', 18)}}的其他基金
Personalized Cystic Fibrosis Therapy and Research Center
个性化囊性纤维化治疗和研究中心
- 批准号:
10017681 - 财政年份:2018
- 资助金额:
$ 23.85万 - 项目类别:
Personalized Cystic Fibrosis Therapy and Research Center
个性化囊性纤维化治疗和研究中心
- 批准号:
10249239 - 财政年份:2018
- 资助金额:
$ 23.85万 - 项目类别:
Personalized Cystic Fibrosis Therapy and Research Center
个性化囊性纤维化治疗和研究中心
- 批准号:
10477249 - 财政年份:2018
- 资助金额:
$ 23.85万 - 项目类别:
Personalized Cystic Fibrosis Therapy and Research Center
个性化囊性纤维化治疗和研究中心
- 批准号:
9532387 - 财政年份:2018
- 资助金额:
$ 23.85万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 23.85万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 23.85万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 23.85万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 23.85万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 23.85万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 23.85万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 23.85万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 23.85万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 23.85万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 23.85万 - 项目类别: